AR087563A1 - Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv) - Google Patents

Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv)

Info

Publication number
AR087563A1
AR087563A1 ARP120103008A ARP120103008A AR087563A1 AR 087563 A1 AR087563 A1 AR 087563A1 AR P120103008 A ARP120103008 A AR P120103008A AR P120103008 A ARP120103008 A AR P120103008A AR 087563 A1 AR087563 A1 AR 087563A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
amino
hydroxy
halogen
Prior art date
Application number
ARP120103008A
Other languages
English (en)
Spanish (es)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47746761&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR087563(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR087563A1 publication Critical patent/AR087563A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/027Organoboranes and organoborohydrides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/04Esters of boric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP120103008A 2011-08-19 2012-08-16 Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv) AR087563A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161525440P 2011-08-19 2011-08-19
US201261650681P 2012-05-23 2012-05-23

Publications (1)

Publication Number Publication Date
AR087563A1 true AR087563A1 (es) 2014-04-03

Family

ID=47746761

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120103008A AR087563A1 (es) 2011-08-19 2012-08-16 Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv)

Country Status (38)

Country Link
US (2) US8927593B2 (enExample)
EP (2) EP2744332B1 (enExample)
JP (2) JP6367712B2 (enExample)
KR (1) KR101913800B1 (enExample)
CN (1) CN103732065B (enExample)
AR (1) AR087563A1 (enExample)
AU (1) AU2012299295B2 (enExample)
BR (1) BR112014002845A2 (enExample)
CA (1) CA2844086A1 (enExample)
CL (2) CL2014000393A1 (enExample)
CO (1) CO6862153A2 (enExample)
CR (1) CR20140078A (enExample)
CY (1) CY1118399T1 (enExample)
DK (1) DK2744332T3 (enExample)
DO (1) DOP2014000034A (enExample)
EA (1) EA032841B1 (enExample)
ES (1) ES2611731T3 (enExample)
HR (1) HRP20161743T1 (enExample)
HU (1) HUE030300T2 (enExample)
IL (1) IL230487B (enExample)
IN (1) IN2014CN00572A (enExample)
JO (1) JO3281B1 (enExample)
LT (1) LT2744332T (enExample)
MA (1) MA35443B1 (enExample)
ME (1) ME02588B (enExample)
MX (1) MX354676B (enExample)
PE (1) PE20141201A1 (enExample)
PH (1) PH12014500385A1 (enExample)
PL (1) PL2744332T3 (enExample)
PT (1) PT2744332T (enExample)
RS (1) RS55462B1 (enExample)
SG (1) SG10201606883QA (enExample)
SI (1) SI2744332T1 (enExample)
SM (2) SMT201700028T1 (enExample)
TW (1) TWI538915B (enExample)
UY (1) UY34274A (enExample)
WO (1) WO2013028371A1 (enExample)
ZA (1) ZA201401020B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2735542T3 (es) 2011-08-17 2019-12-19 Glaxosmithkline Llc Procedimientos terapéuticos
US8927593B2 (en) 2011-08-19 2015-01-06 Glaxo Group Limited Benzofuran compounds for the treatment of hepatitis C virus infections
US10308937B2 (en) * 2014-11-10 2019-06-04 Glaxosmithkline Intellectual Property (No. 2) Limited Combination long acting compositions and methods for Hepatitis C
CA2967195A1 (en) 2014-11-10 2016-05-19 Glaxosmithkline Intellectual Property (No.2) Limited Long acting pharmaceutical compositions for hepatitis c
KR20180006522A (ko) 2016-07-07 2018-01-18 삼성디스플레이 주식회사 액정 조성물 및 이를 포함하는 액정 표시 장치
US11738088B2 (en) 2016-08-01 2023-08-29 University of Pittsburgh—of the Commonwealth System of Higher Education Boryl ethers, carbonates, and cyclic acetals as oxidatively-triggered drug delivery vehicles
EP3589630B1 (en) * 2017-03-02 2021-07-07 Assembly Biosciences, Inc. Cyclic sulfamide compounds and methods of using same
MA51611A (fr) * 2018-01-17 2021-04-21 Glaxosmithkline Ip Dev Ltd Inhibiteurs de pi4kiiibêta
EP4049680A4 (en) * 2019-10-25 2024-01-10 Sumitomo Pharma Co., Ltd. NEW SUBSTITUTED CONDENSED RING CONNECTION
CN111026203B (zh) * 2019-12-02 2021-01-26 宁波德晶元科技有限公司 一种适用于真空热水壶的加热控制方法与系统

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
AU5920400A (en) * 1999-07-07 2001-01-22 Du Pont Pharmaceuticals Company Cell-based assay systems for examining hcv ns3 protease activity
ES2571219T3 (es) 2001-01-25 2024-09-23 The United States Of America Represented By The Sec Dep Of Health And Human Services Formulación de compuestos de ácido borónico
BR0315937A (pt) * 2002-11-01 2005-09-13 Viropharma Inc Composto, composição para a profilaxia ou tratamento de infecções virais, e, método para a profilaxia ou tratamento de infecções da hepatite c e doenças associadas com tais infecções em um hospedeiro vivo
WO2008051244A2 (en) 2005-12-01 2008-05-02 Wyeth Anthranilic acid derivatives useful in treating infection with hepatitis c virus
DK1988779T5 (en) 2006-02-16 2016-10-10 Anacor Pharmaceuticals Inc SMALL boron MOLECULES AS ANTI-INFLAMMATORY AGENTS
CA2651212A1 (en) * 2006-05-02 2007-11-15 Anacor Pharmaceuticals, Inc. Hydrolytically-resistant boron-containing therapeutics and methods of use
US20070286822A1 (en) 2006-06-12 2007-12-13 Anacor Pharmaceuticals Inc. Compounds for the Treatment of Periodontal Disease
EP3150589A1 (en) 2007-06-08 2017-04-05 MannKind Corporation Ire-1a inhibitors
GB0719366D0 (en) * 2007-10-03 2007-11-14 Smithkline Beecham Corp Compounds
WO2009111676A2 (en) 2008-03-06 2009-09-11 Anacor Pharmaceuticals, Inc Boron-containing small molecules as anti-inflammatory agents
CN101910145A (zh) * 2008-02-14 2010-12-08 弗·哈夫曼-拉罗切有限公司 抗病毒的杂环化合物
WO2009137500A1 (en) * 2008-05-05 2009-11-12 Wyeth 6-substituted benzofuran compounds to treat infection with hepatitis c virus
WO2009137493A1 (en) 2008-05-05 2009-11-12 Wyeth 2-substituted benzofuran compounds to treat infection with hepatitis c virus
TW201008933A (en) 2008-08-29 2010-03-01 Hutchison Medipharma Entpr Ltd Pyrimidine compounds
EP2348863A4 (en) 2008-09-04 2012-03-07 Anacor Pharmaceuticals Inc BORN SMALL MOLECULES
WO2011050284A1 (en) * 2009-10-23 2011-04-28 Glaxosmithkline Llc Pyrazolylpyridine antiviral agents
WO2011103063A1 (en) 2010-02-19 2011-08-25 Glaxo Group Limited Therapeutic compounds
WO2011106929A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase
TW201136919A (en) 2010-03-02 2011-11-01 Merck Sharp & Amp Dohme Corp Inhibitors of hepatitis C virus NS5B polymerase
WO2011106986A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase
TW201221518A (en) 2010-11-18 2012-06-01 Glaxo Group Ltd Compounds
WO2012067663A1 (en) 2010-11-18 2012-05-24 Glaxo Group Limited Compounds
ES2735542T3 (es) * 2011-08-17 2019-12-19 Glaxosmithkline Llc Procedimientos terapéuticos
WO2013025975A1 (en) * 2011-08-17 2013-02-21 Glaxosmithkline Llc Combination treatments for hepatitis c
US8927593B2 (en) 2011-08-19 2015-01-06 Glaxo Group Limited Benzofuran compounds for the treatment of hepatitis C virus infections

Also Published As

Publication number Publication date
EA032841B1 (ru) 2019-07-31
PL2744332T3 (pl) 2017-03-31
BR112014002845A2 (pt) 2017-02-21
TWI538915B (zh) 2016-06-21
CR20140078A (es) 2014-03-20
KR101913800B1 (ko) 2018-11-01
AU2012299295B2 (en) 2016-03-31
US8927593B2 (en) 2015-01-06
JP2017125010A (ja) 2017-07-20
ES2611731T3 (es) 2017-05-10
PE20141201A1 (es) 2014-10-03
IN2014CN00572A (enExample) 2015-04-03
LT2744332T (lt) 2017-01-10
RS55462B1 (sr) 2017-04-28
MA35443B1 (fr) 2014-09-01
CN103732065B (zh) 2016-10-26
CY1118399T1 (el) 2017-06-28
EP2744332B1 (en) 2016-10-26
US20150080343A1 (en) 2015-03-19
JP6367712B2 (ja) 2018-08-01
IL230487B (en) 2019-06-30
IL230487A0 (en) 2014-03-31
SMT201700028T1 (it) 2017-03-08
PH12014500385A1 (en) 2020-06-22
MX2014001989A (es) 2014-02-27
AU2012299295A1 (en) 2014-02-20
EP3199531A1 (en) 2017-08-02
CA2844086A1 (en) 2013-02-28
HUE030300T2 (en) 2017-04-28
EP2744332A1 (en) 2014-06-25
WO2013028371A1 (en) 2013-02-28
DK2744332T3 (en) 2017-01-16
CN103732065A (zh) 2014-04-16
MX354676B (es) 2018-03-15
EP2744332A4 (en) 2015-01-14
TW201321390A (zh) 2013-06-01
CL2014000393A1 (es) 2014-08-01
SG10201606883QA (en) 2016-10-28
JO3281B1 (ar) 2018-09-16
CO6862153A2 (es) 2014-02-10
US20130237501A1 (en) 2013-09-12
US9682999B2 (en) 2017-06-20
EA201490213A1 (ru) 2014-07-30
SI2744332T1 (sl) 2017-01-31
PT2744332T (pt) 2017-01-24
HRP20161743T1 (hr) 2017-02-24
DOP2014000034A (es) 2014-06-01
CL2017000293A1 (es) 2017-10-06
SMT201700028B (it) 2017-03-08
ZA201401020B (en) 2020-11-25
ME02588B (me) 2017-06-20
KR20140054287A (ko) 2014-05-08
UY34274A (es) 2013-04-05
JP2014527529A (ja) 2014-10-16

Similar Documents

Publication Publication Date Title
AR087563A1 (es) Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv)
AR087793A1 (es) Compuestos de benzofurano sustituido y metodos para el uso de los mismos en el tratamiento de enfermedades virales
AR113964A1 (es) Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa
AR112216A1 (es) Derivados de azaquinolina
AR087791A1 (es) Derivados de benzofurano con sustitucion heterociclica y metodos para el uso de los mismos en el tratamiento de enfermedades virales
AR120338A1 (es) Piridazinonas como inhibidores de parp7
AR113818A2 (es) Pirazolo-quinazolinas como inhibidores de proteína quinasa
AR091279A1 (es) Inhibidores macrociclicos de virus flaviviridae
AR100438A1 (es) Pirazolopiridinas y pirazolopirimidinas
AR089143A1 (es) Triazolopiridinas sustituidas con actividad inhibidora de ttk
AR079689A1 (es) Derivados de imidazo[1,2a]piridina, composiciones farmaceuticas que los comprenden y uso de los mismos en trastornos mieloproliferativos, leucemia y enfermedades inmunologicas e inflamatorias.
AR090572A1 (es) Derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos
AR088029A1 (es) Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central
AR099955A1 (es) Compuestos de heteroarilo o arilo bicíclicos fusionados
AR095311A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
AR104025A1 (es) Carbamatos de piperazina como moduladores de magl y/o abhd6, procesos para su preparación y composiciones farmacéuticas
AR087607A1 (es) Derivados de piridazinona
AR051753A1 (es) Metodos para preparar compuestos de indazol
AR084553A1 (es) DERIVADOS IMIDAZOLICOS HETEROCICLICOS INHIBIDORES DE b-SECRETASA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USO DE LOS MISMOS PARA TRATAR ENFERMEDADES NEURODEGENERATIVAS, EN PARTICULAR ALZHEIMER
AR089285A1 (es) Derivados de betulina
AR087792A1 (es) Compuestos heterociclicos tetraciclicos y metodos para el uso de los mismos en el tratamiento de enfermedades virales
AR088474A1 (es) Derivados de alcoholes de 1-fenil-2-piridinilalquilo como inhibidores de la fosfodiesterasa
AR100418A1 (es) Compuestos y composiciones para inducir condrogénesis
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR126693A1 (es) Compuestos de pirazolopiridinona

Legal Events

Date Code Title Description
FB Suspension of granting procedure